Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: Clinical relevance and effects of cytokine therapy

Clinical Cancer Research

Volumn 4, Issue 10, 1998, Pages 2337-2347

  Bukowski, Ronald M ^a,b   Rayman, Patricia ^b   Uzzo, Robert ^b   Bloom, Tracy ^b   Sandstrom, Kati ^a   Peereboom, David ^a,b   Olencki, Thomas ^a,b   Budd, G Thomas ^a,b   McLain, Denise ^a   Elson, Paul ^b   Novick, Andrew ^b   Finke, James H ^a,b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD3 ANTIGEN; CYTOKINE; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IONOMYCIN; MONOCLONAL ANTIBODY; PHORBOL 13 ACETATE 12 MYRISTATE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR;

ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CANCER; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

CARCINOMA, RENAL CELL; CYTOKINES; HUMANS; KIDNEY NEOPLASMS; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); MEMBRANE PROTEINS; NF-KAPPA B; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 0031722032     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Mizoguchi, H., O'Shea, J. J., Longo, D. L., Loeffler, C. M., McVicar, D. W., and Ochoa, A. C. Alterations in signal transaction molecules in T lymphocytes from tumor bearing mice. Science (Washington DC), 258: 1795-1798, 1992.
2. 1ck in T-cells infiltrating human renal cell carcinoma. Cancer Res., 55: 5613-5616, 1993.
3. Rabinowich, H., Banks, M., Reichert, T. E., Logan, T. F., Kirkwood, J. M., and Whiteside, T. L. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin. Cancer Res., 2: 1263-1274, 1996.
4. Zea, A. H., Curti, B. D., Longo, D. L., Alvord, W. G., Strobl, S. L., Mizoguchi, H., Creekmore, S. P., O'Shea, J. J., Powers, G. C., Urba, W. J., and Ochoa, A. C. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin. Cancer Res., 1: 1327-1335, 1995.
5. Tartour, E., Latour, S., Mathiot, C., Thiounn, N., Mosseri, V., Joyeux, I., D'Enghien, C. D., Lee, R., Debre, B., and Fridman, W. H. Variable expression of CD3-ζ chain in tumor infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int. J. Cancer, 63: 205-212, 1995.
6. Lai, P., Rabinowich, H., Crowley-Nowick, P. A., Bell, M. C., Mantovani, G., and Whiteside, T. L. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin. Cancer Res., 2: 161-173, 1996.
7. Renner, C., Ohnesorge, S., Held, G., Bauer, S., Jung, W., Pfitzenmeier, J., and Pfreundschuh, M. T-cells from patients with Hodgkin's disease have a defective T-cell receptor C chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood, 88: 236-241, 1996.
8. Nakagomi, H., Petersson, M., Magnusson, I., Juhlin, C., Matsuda, M., Mellstedt, H., Taupin, J. L., Vivier, E., Anderson, P., and Kiessling, R. Decreased expression of the signal-transducing ζ chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res., 53: 5610-5612, 1993.
9. Matsuda, M., Peterson, M., Lenkei, R., Taupin, J. L., Magnusson, I., and Mellstedt, H. Alterations in the signal-transducing molecules of T-cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int. J. Cancer, 61: 765-772, 1995.
10. Ghosh, P., Sica, A., Young, H. A., Ye, J., Franco, J. L., Wiltrout, R. H., Longo, D. L., Rice, N. R., and Komschlies, K. L. Alterations in NFκB/rel family proteins in splenic T-cells from tumor bearing mice and reversal following therapy. Cancer Res., 54: 2969-2972, 1994.
11. Li, X., Liu, J., Park, J. K., Hamilton, T. A., Rayman, P., Klein, E., Edinger, M., Tubbs, R., Bukowski, R., and Finke, J. T-cells from renal cell carcinoma patients exhibit an abnormal pattern of κB-specific DNA binding activity: a preliminary report. Cancer Res., 54: 5424-5429, 1994.
12. Miescher, S., Stoeck, M., Qiao, L., Barros, C., Barrelet, L., and von Fliedner, V. Proliferative and cytolytic potentials of purified human tumor-infiltrating T-lymphocytes. Impaired response to mitogen-driven stimulation despite T-cell receptor expression. Int. J. Cancer, 42: 659-666, 1988.
13. Alexander, J. P., Kudoh, S., Melsop, K. A., Hamilton, T. A., Edinger, M. G., Tubbs, R. R., and Sica, D. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin-2 and express interleukin-2 receptors. Cancer Res., 53: 1380-1387, 1993.
14. Vitolo, D., Zerbe, T., Kanbour, A., Dahl, C., Herberman, R. B., and Whiteside, T. L. Expression of mRNA for cytokines in tumor-infiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer. Int. J. Cancer, 51: 573-580, 1992.
15. Ghosh, P., Komschlies, K. L., Cippitelli, M., Longo, D. L., Subleski, J., Ye, J., Sica, A., Young, H. A., Wiltrout, R. H., and Ochoa, A. C. Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J. Natl. Cancer Inst., 87: 1478-1483, 1995.
16. Schreiber, E., Matthias, E., Muller, M. M., and Schaffner, W. Rapid detection of octamer binding proteins with Amini-extracts prepared from a small number of cells. Nucleic Acids Res, 17: 6419, 1989.
17. Osborn, L., Kunkel, S., and Nabel, G. J. Tumor necrosis factor a and interleukin-1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor KB. Proc. Natl. Acad. Sci. USA, 86: 2336-2340, 1989.
18. Wilcoxon, F. Individual comparisons by ranking methods. Biometrics, 1: 80-83, 1945.
19. Kleinbaum, D. G., Kupper, L. L., and Muller, K. E. Applied Regression Analysis and Other Multivariable Methods, pp. 102-143. Boston: PWS-KENT Publishing Company, 1988.
20. John, P. W. Statistical Design and Analysis of Experiments, pp. 39-81. New York: The Macmillan Company, 1971.
21. Steel, R. G. D., and Torrie, J. H. Principles and Procedures of Statistics, Ed. 2, pp. 111-113. New York: McGraw-Hill Book Co., 1980.
22. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem. Rep., 50: 163-170, 1966.
23. Bukowski, R. M., Olencki, T., Wang, Q., Peereboom, D., Budd, G. T., Elson, P., Sandstrom, K., Tuason, L., Rayman, P., and Tubbs, R. Phase II trial of interleukin-2 and interferon-α in patients with renal cell carcinoma: clinical results and immunologic correlates of response. J. Immunother., 20: 301-311, 1997.
24. Olencki, T., Bukowski, R. M., Budd, G. T., Peereboom, D., McLain, D., Sandstrom, K., Finke, J., and Elson, P. Phase I/II trial of simultaneously administered rIL-2/rHuIFNα2a and 5-FU in patients (PTS) with metastatic renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol., 15: 263, 1996.
25. Salvadori, S., Gansbacher, B., Pizzimenti, A. M., and Zier, K. S. Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2 secreting tumors. J. Immunol., 153: 5176-5182, 1994.
26. Renner, C., Ohnesorge, S., Held, G., Bauer, S., Jung, W., Pfitzenmeier, J. P., and Pfreundschuh, M. T cells from patients with Hodgkin's disease have a defective T-cell receptor ζ chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood, 88: 236-241, 1996.
27. + associated kinases are present. J. Immunol., 155: 1382-1392, 1995.
28. Cardi, G., Heaney, J. A., Schnol, A. L., Phillip, D. M., Branda, M. T., and Ernstoff, M. S. T-cell receptor S-chain expression or tumor infiltrating lymphocytes from renal cell carcinoma. Cancer Res., 57: 3517-3519, 1997.
29. Farace, F., Angevin, E., Vanderplancke, J., Escudier, B., and Triebel, F. The decreased expression of CD3ζ chains in cancer patients is not reversed by IL-2 administration. Int. J. Cancer, 59: 752-755, 1994.
30. Baeuerle, P. A., and Baltimore, D. NFκB: ten years after. Cell, 87: 13-20, 1996.
31. + T lymphocytes. Science (Washington DC). 256: 1452-1456, 1992.
32. Sikora, E., Kaminska, B., Radziszewska, E., and Kaczmarek, L. Loss of transcription factor AP-1 DNA binding activity during lymphocyte aging in vitro. FEBS Lett., 312: 179-182, 1992.
33. Whisler, R. L., Beiqing, L., and Chen, M. Age-related decreases in IL-2 production by human T cells are associated with impaired activation of nuclear transcriptional factors AP-1 and NF-AT. Cell Immunol., 169: 185-195, 1996.
34. Verma, I. M., Stevenson, J. K., Schwarz, E. M., Van Antwerp, D., and Miyamoto, S. Rel/NFκB/I6B family: intimate tales of association and disassociation. Genes Dev., 9: 2723-2735, 1995.
35. Correa, M. R., Ochoa, A. C., Ghosh, P., Mizoguchi, H., Harvey, L., and Longo, D. L. Sequential development of structural and functional alterations on T-cells from tumor-bearing mice. J. Immunol., 158: 5292-5296, 1997.
36. Miescher, S., Whiteside, T. L., Carrel, S., and Von Fliedner, V. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J. Immunol., 136: 1899-1907, 1986.
37. O'Mahony, A. M., O'Sullivan, G. C., O'Connell, J., Cotter, T. G., and Collins, J. K. An immune suppressive factor derived from esophageal squamous carcinoma induces apoptosis in normal and transformed cells of lymphoid lineage. J. Immunol., 151: 4847-4856, 1993.
38. Kono, K., Salazar-Onfray, F., Petersson, M., Hansson, J., Masucci, G., and Wasserman, K. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing ζ molecules and inhibits tumor-specific T-cell and natural killer cell-mediated cytotoxicity. Eur. J. Immunol., 26: 1308-1313, 1996.
39. Otsuji, M., Kimura, Y., Aoe, T., Okamoto, Y., and Saito, T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3ζ chain of T-cell receptor complex and antigen-specific T-cell responses. Proc. Natl. Acad. Sci. USA, 93: 13119-13124, 1996.
40. Guarini, A., Riera, L., Cignetti, A., Montacchini, L., Massaia, M., and Foa, R. Transfer of the interleukin-2 gene into human cancer cells induces specific antitumor recognition and restores the expression of CD3/T-cell receptor associated signal transduction molecules. Blood, 89: 212-218, 1997.
41. Ling, W., Rayman, P., Uzzo, R., Clark, P., Kim, H. J., Tubbs, R., Novick, A., Bukowski, R., Hamilton, T., and Finke, J. Impaired activation of NFκB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IκBa. Blood, 92: 1334-1341, 1998.